Subcutaneous injection deposits IGF-1 LR3 into the fatty layer just under the skin (commonly the abdomen, around 2-3 inches from the navel, or the upper thigh)
Different patient populations, different trial designs, different enrollment criteria, and different measurement protocols all introduce noise that makes precise numerical comparisons between CagriSema and tirzepatide unreliable
Both outcomes are possible
Possible side effects Side effects can vary and may include: Injection-site irritation (redness, tenderness, swelling) Headache, fatigue, or dizziness (reported anecdotally/observationally) Digestive discomfort in some individuals Contraindications & precautions BPC-157 may not be appropriate for everyone
It strips away the dendritic branches and synaptic connections that surviving neurons need to communicate
How does KPV compare to BPC-157 for gut healing